NCT01922102 - Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia | Biotech Hunter

Enrollment

457

Participants

Timeline

Start Date

September 11, 2013

Primary Completion Date

September 14, 2016

Study Completion Date

September 14, 2016

Conditions

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

Interventions

DRUG

Ranibizumab 0.5mg

0.5 mg ranibizumab (intravitreal injections)

DRUG

Ranibizumab 0.5 mg

0.5 mg ranibizumab (intravitreal injections)

DRUG

Verteporfin PDT

Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application

Trial Locations (47)

1000

Novartis Investigative Site, Manila

1008

Novartis Investigative Site, Manila

10700

Novartis Investigative Site, Bangkok

40002

Novartis Investigative Site, Khon Kaen

50200

Novartis Investigative Site, Chiang Mai

73210

Novartis Investigative Site, Nakornphathom

100034

Novartis Investigative Site, Beijing

100176

Novartis Investigative Site, Beijing

100191

Novartis Investigative Site, Beijing

100730

Novartis Investigative Site, Beijing

110029

Novartis Investigative Site, New Delhi

150001

Novartis Investigative Site, Harbin

200080

Novartis Investigative Site, Shanghai

200092

Novartis Investigative Site, Shanghai

210006

Novartis Investigative Site, Nanjing

210029

Novartis Investigative Site, Nanjing

214023

Novartis Investigative Site, Wuxi

266011

Novartis Investigative Site, Qingdao

300020

Novartis Investigative Site, Tianjin

300070

Novartis Investigative Site, Tianjin

310009

Novartis Investigative Site, Hangzhou

325027

Novartis Investigative Site, Wenzhou

330006

Novartis Investigative Site, Nanchang

400038

Novartis Investigative Site, Chongqing

400042

Novartis Investigative Site, Chongqing

410008

Novartis Investigative Site, Changsha

410011

Novartis Investigative Site, Changsha

430060

Novartis Investigative Site, Wuhan

430070

Novartis Investigative Site, Wuhan

515041

Novartis Investigative Site, Shantou

600006

Novartis Investigative Site, Chennai

610041

Novartis Investigative Site, Chengdu

683572

Novartis Investigative Site, Angamaly

695035

Novartis Investigative Site, Vanchiyoor

710032

Novartis Investigative Site, Xi’an

751024

Novartis Investigative Site, Bhubaneswar

Unknown

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Hong Kong

160 030

Novartis Investigative Site, Chandīgarh

560 010

Novartis Investigative Site, Bangalore

600 015

Novartis Investigative Site, Chennai

641 014

Novartis Investigative Site, Coimbatore

500 034

Novartis Investigative Site, Hyderabad

614 735

Novartis Investigative Site, Pusan

02841

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul